| In millions, except per share items | Jun-30-17 | Mar-31-17 | Dec-31-16 | Sep-30-16 | Jun-30-16 | Mar-31-16 | Dec-31-15 | Sep-30-15 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| U.S. Medical | 61.6 | 58.4 | 59.0 | 57.0 | 56.3 | 53.0 | 54.6 | 51.9 |
| International Medical | 13.1 | 11.3 | 12.9 | 11.3 | 11.4 | 9.9 | 10.6 | 9.7 |
| Total revenues | 74.7 | 69.7 | 71.9 | 68.3 | 67.7 | 62.9 | 65.2 | 61.7 |
| Revenue growth [+] | 10.3% | 10.8% | 10.3% | 10.7% | 9.8% | 9.5% | 3.6% | 4.9% |
| U.S. Medical | 9.3% | 10.3% | 8.1% | 9.8% | 9.2% | 9.0% | 4.3% | 7.2% |
| International Medical | 15.0% | 13.8% | 21.7% | 15.8% | 13.2% | 12.2% | -0.1% | -5.8% |
| Cost of goods sold | 18.5 | 18.1 | 18.4 | 16.9 | 17.0 | 16.1 | 16.1 | 15.8 |
| Gross profit | 56.2 | 51.6 | 53.5 | 51.4 | 50.8 | 46.8 | 49.1 | 45.9 |
| Gross margin | 75.3% | 74.1% | 74.5% | 75.3% | 74.9% | 74.4% | 75.3% | 74.4% |
| Selling, general and administrative [+] | 45.5 | 45.7 | 42.1 | 40.7 | 40.6 | 40.8 | 36.7 | 34.1 |
| General and administrative | | | 42.1 | | | | 36.7 | |
| Other operating expenses | 22.8 | 20.8 | 19.7 | 19.7 | 20.9 | 19.6 | 17.4 | 16.3 |
| EBITDA [+] | 1.6 | -8.0 | -1.4 | -2.3 | -3.8 | -6.7 | 1.9 | 2.2 |
| EBITDA growth | -140.8% | 18.3% | -173.7% | -207.2% | -130.2% | -22.6% | 40.8% | 16.6% |
| EBITDA margin | 2.1% | -11.4% | -1.9% | -3.4% | -5.7% | -10.7% | 2.9% | 3.5% |
| Depreciation | 7.9 | 3.9 | 3.9 | 3.8 | 3.8 | 3.7 | 3.7 | 3.4 |
| EBITA | -6.3 | -11.9 | -5.3 | -6.1 | -7.6 | -10.4 | -1.8 | -1.2 |
| EBITA margin | -8.4% | -17.0% | -7.4% | -9.0% | -11.2% | -16.6% | -2.8% | -2.0% |
| Amortization of intangibles | 5.8 | 2.9 | 2.9 | 2.9 | 3.2 | 3.2 | 3.2 | 3.3 |
| EBIT [+] | -12.1 | -14.8 | -8.2 | -9.0 | -10.8 | -13.6 | -5.0 | -4.5 |
| EBIT growth | 12.3% | 8.6% | 63.3% | 99.6% | -284.7% | -8.1% | 11.2% | 17.0% |
| EBIT margin | -16.2% | -21.2% | -11.5% | -13.2% | -15.9% | -21.7% | -7.7% | -7.3% |
| Non-recurring items [+] | 9.2 | 0.2 | 0.3 | 0.8 | 0.5 | 0.3 | 2.6 | 7.9 |
| Asset impairment | | | | | | | | 2.5 |
| Interest expense | 3.6 | 3.4 | 3.3 | 3.3 | 3.3 | 3.3 | 2.4 | 1.9 |
| Interest expense | 3.6 | 3.4 | 3.3 | 3.3 | 3.3 | 3.3 | 2.4 | 1.9 |
| Other income (expense), net [+] | 0.7 | 0.1 | -0.4 | 0.0 | -0.2 | 0.2 | -0.1 | 0.0 |
| Gain (loss) on foreign currency transactions | 0.7 | 0.1 | -0.4 | 0.0 | -0.2 | 0.2 | -0.1 | 0.0 |
| Change in value of contingent liability | | | | | | | -3.8 | -4.3 |
| Other | | | -3.8 | -3.3 | | | -2.6 | -1.9 |
| Pre-tax income | -24.2 | -18.3 | -12.3 | -13.2 | -14.8 | -17.1 | -10.2 | -14.3 |
| Income taxes | 0.4 | 0.2 | 0.3 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 |
| Tax rate | | | | | | | | |
| Net income | -24.6 | -18.5 | -12.6 | -13.3 | -14.9 | -17.3 | -10.5 | -14.5 |
| Net margin | -32.9% | -26.6% | -17.5% | -19.5% | -22.0% | -27.5% | -16.0% | -23.5% |
| |
| Basic EPS [+] | ($0.56) | ($0.43) | ($0.29) | ($0.31) | ($0.35) | ($0.40) | ($0.25) | ($0.34) |
| Growth | 61.6% | 5.2% | 19.1% | -9.2% | 104.6% | -37.5% | -35.8% | 2.1% |
| Diluted EPS [+] | ($0.56) | ($0.43) | ($0.29) | ($0.31) | ($0.35) | ($0.40) | ($0.25) | ($0.34) |
| Growth | 61.6% | 5.2% | 19.1% | -9.2% | 104.6% | -37.5% | -35.8% | 2.1% |
| |
| Shares outstanding (basic) [+] | 43.7 | 43.5 | 42.9 | 43.1 | 42.8 | 42.7 | 42.4 | 42.6 |
| Growth | 2.2% | 1.9% | 1.2% | 1.2% | 1.0% | 1.3% | 1.8% | 1.8% |
| Shares outstanding (diluted) [+] | 43.7 | 43.5 | 42.9 | 43.1 | 42.8 | 42.7 | 42.4 | 42.6 |
| Growth | 2.2% | 1.9% | 1.2% | 1.2% | 1.0% | 1.3% | 1.8% | 1.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |